Skip to content

Ketamine: all studies

Page 124 of 448: studies 1,231 to 1,240 of 4,475, newest first. Back to the ketamine overview

Research

Potential effect of ketamine in treatment for dextromethorphan use disorder exploding in Japanese young population.

Asian Journal of Psychiatry September 1, 2024 Kaori Ishii, Kyoji Okita 1 citation

In Japan, the landscape of clinical practice for substance use disorder is changing significantly, primarily due to an increase in patients using over-the-counter drugs. A major concern is the rising number of patients misusing dextromethorphan (DXM). These patients with DXM use disorders often have severe trauma-related and mood symptoms, and therefore try to cope with those symptoms by...

DOI: 10.1016/j.ajp.2024.104164 (opens in new tab) Full text (opens in new tab) Anxiety Dextromethorphan Over-the-counter medication Self medication +11

A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression.

Asian Journal of Psychiatry September 1, 2024 Pn Suresh Kumar, Vikas Menon, Chittaranjan Andrade 12 citations

For depression, ketamine is more conveniently administered by oral than by intravenous (iv) routes. The relative antidepressant efficacy of oral vs iv ketamine is unknown. To assess the acute efficacy and the persistence of improvement with open-label oral versus iv ketamine in outpatients with treatment-resistant depression (TRD). Adults with TRD were randomized to oral (N=30) or IV (N=31)...

Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence.

Schizophrenia Research September 1, 2024 Ana Teresa Caliman-Fontes, Flávia Vieira, Gustavo C. Leal et al. 7 citations

Catatonia, documented since the 19th century, remains a significant challenge in terms of recognition and treatment. Over the last two decades, ketamine has brought new perspectives to psychiatry, sparking widespread interest. Concurrently, catatonia has attracted heightened scientific attention. Preliminary evidence suggests the therapeutic potential of ketamine for catatonia. We...

DOI: 10.1016/j.schres.2024.07.055 (opens in new tab) Full text (opens in new tab) Esketamine Mental-health Psychiatric-treatment Ketamine-therapy +2

Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression.

JAAPA September 1, 2024 Carolyn F Kundert, Robert M Sobule, Muaid Ithman 1 citation

Esketamine, the s(+) enantiomer of ketamine, was approved in 2019 as the first rapid-acting intranasal spray medication for treatment-resistant depression; the drug is given in combination with an antidepressant. The treatment is self-administered in a clinical setting under the supervision of a healthcare provider and usually is well tolerated. Many of its adverse reactions are mild,...

DOI: 10.1097/01.JAA.0000000000000036 (opens in new tab) Full text (opens in new tab) Depression treatment Cognitive side effects Esketamine therapy Mental health research +1

Exploring perinatal ketamine for postpartum depression following cesarean section: A systematic review.

Psychiatry and Clinical Neurosciences Reports September 1, 2024 Jaylyn Thompson, David F Lo, Alexis Foschini et al. 1 citation

The aim of this study was to explore the use of perinatal ketamine to see if it can be used for the reduction of postpartum depression (PPD) following cesarean section (C-section). PubMed, Cochrane, and Web of Science were the primary databases used for this review. Search terms used on January 5, 2024 incorporated "ketamine," "C-section," "postpartum depression," and related synonyms. The...

DOI: 10.1002/pcn5.70004 (opens in new tab) Full text (opens in new tab) Perinatal ketamine Postpartum depression ppd Postnatal depression Cesarean section c-section +2

Different development patterns of reward behaviors induced by ketamine and JWH-018 in striatal GAD67 knockdown mice.

Journal of veterinary science September 1, 2024 Sun Mi Gu, Eunchong Hong, Sowoon Seo et al. 1 citation

Glutamic acid decarboxylase 67 (GAD67) is a gamma-aminobutyric acid (GABA) synthesis enzyme associated with the function of other neurotransmitter receptors, such as the N-methyl-D-aspartate (NMDA) receptor and cannabinoid receptor 1. However, the role of GAD67 in the development of different abused drug-induced reward behaviors remains unknown. In order to elucidate the mechanisms of substance...

DOI: 10.4142/jvs.23325 (opens in new tab) Full text (opens in new tab) Gad67 Jwh-018 Conditioned place preference Gamma-aminobutyric acid +5

Ketamine and α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Potentiation in the Somatosensory Cortex: A Comprehensive Review.

Cureus September 1, 2024 Kaustuv Das, Jayshree Sen, Aishwarya S Borode

Ketamine, a dissociative anesthetic primarily recognized for its antagonism of N-methyl-D-aspartate (NMDA) receptors, has gained significant attention for its rapid antidepressant effects and potential in treating mood disorders. However, recent research indicates that ketamine's influence extends beyond NMDA receptor inhibition, affecting α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid...

Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.

Psychedelic Medicine September 1, 2024 Zarmeen Zahid, Ziyad W. Sultan, Bryan M Krause et al. 5 citations

Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that despite having distinct molecular targets, both drugs may exert therapeutic benefit via their pro-neuroplastic effects. Following treatment with ketamine or serotonergic psychedelics, patients are reported to be more open to behavioral change, which...

DOI: 10.1089/psymed.2023.0061 (opens in new tab) Full text (opens in new tab) Psychedelic-therapy Brain-plasticity Mental-health Pharmacology

A Case Report of Ketamine-induced Hypoglycemia in Treatment Resistance Depression.

Clinical Psychopharmacology and Neuroscience August 31, 2024 Juthawadee Lortrakul, Keerati Pattanaseri 1 citation

Ketamine therapy can reduce the risk of suicide and depression in the treatment resistant patient. Adverse effects of ketamine infusion include blurred vision, nausea and vomiting, hepatotoxicity, headache, and cystitis. However, the effect of ketamine infusion on blood glucose remains unclear. This report describes several episodes of hypoglycemia in a 36-year-old man with type 1 diabetes...

Electroconvulsive therapy versus intravenous ketamine as a novel treatment in depressive disorders: Review of the literature

Medical Science August 30, 2024 Marcin Głód, Dominika Kabała, Adam Jaskulski et al.

Aim: In this review, we assessed the state of available knowledge regarding the antidepressant action of intravenous ketamine versus electroconvulsive therapy (ECT) in randomized clinical trials and clinical trials. Methods: To search for the eligible articles, the PubMed database was used. Five studies were selected using the inclusion criteria, and their findings are presented in our review....